Principal Investigators

    A.Schapira, F.Blandini, D.Di Monte, P.Ciana, D.Park



    Contact information of lead PI


    United Kingdom|Italy|Germany|Canada

    Title of project or programme

    GBA-PARK: GBA1 mutations in Parkinson disease: clinical and biochemical prodrome, risk profile and pathogenetic modelling for therapeutic intervention

    Source of funding information


    Total sum awarded (Euro)

    € 1,447,501

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Parkinson's disease & PD-related disorders


    Research Abstract

    Changes in the GBA gene are found in approximately 10% of patients with Parkinson disease (PD). This represents the most important risk factor for PD discovered to date. Each GBA mutation carrier has up to a 30x increased risk for developing PD during his or her life. Research to date shows that individuals with the GBA mutation begin to show early changes in certain features such as loss of smell, subtle movement problems etc. Together with certain alterations in blood and spinal fluid, these clinical findings can be used to identify the group most at risk of developing PD amongst GBA mutation carriers. In addition, even PD patients without mutations of this gene show alterations of the activity of the GBA enzyme in the brain. This means that some of the lessons we learn from GBA car- riers may be applicable to PD patients in general. This overlap of GBA-related PD to PD in general is particularly important in terms of developing therapies that might be applicable to all PD. The project partners have developed large cohorts of GBA mutation carriers and propose to harmo- nize the study of these individuals across countries. This will provide a very large group with which to study the evolution of PD from its earliest stages before diagnosis and to develop a biomarker profile to identify those most at risk of PD. The researchers are also actively pursuing the study of how GBA mutations cause PD and have already identified a new potential drug class (small molecule chape- rones) that have shown promise in cell and animal models of GBA-related PD. The project partners will collaborate in the use of these models, as well as samples taken from patients, to further develop and test these agents towards their use in clinical trials.

    Lay Summary

    Further information available at:

Types: Investments > €500k, JPND Projects
Member States: Canada, Germany, Italy, JPND, United Kingdom
Diseases: Parkinson's disease & PD-related disorders
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF